Acute toxicity studies of ebrotidine.
The acute toxicity of two formulations of ebrotidine (N-[N-[(E)-[[2-[[[2-[(diaminomethylene)amino]-4-thiazolyl] methyl]thio]ethyl]amino]methylene]-4-bromo-benzenesulfonamide, CAS 100981-43-9, FI-3542) was studied in rats and mice by different routes of dosing: oral and intraperitoneal routes in rats and mice (suspension), intravenous and oral routes in mice and intravenous route in rats (injectable solution). LD50 values for the oral route were indeterminable in all cases. For the intraperitoneal route. LD50 values were 316 mg/kg (rat) and 366 mg/kg (mouse), and for the intravenous route LD50 values were 100 mg/kg (rat) and 107 mg/kg (mouse).
Grau
M T
MT
Centro de Investigación Farmacéutica Grupo Ferrer, Barcelona, Spain.
Romero
A
A
Villamayor
F
F
Sacristán
A
A
Ortiz
J A
JA
D000284:Administration, Oral; D000818:Animals; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000633:toxicity*; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D051381:Rats; D017207:Rats, Sprague-Dawley; D013047:Specific Pathogen-Free Organisms; D013844:Thiazoles / Q000008:administration & dosage / Q000633:toxicity*
D001557:Benzenesulfonates; D006635:Histamine H2 Antagonists; D013844:Thiazoles; C075156:ebrotidine